Denise Weaver, MD
Infectious Disease · Hobart, INNPI 1093772378
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,137 of the $8,352 with a category attached, or 85.4%. It is spread thinly across 47 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among infectious disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$909
- AbbVie$665
- Merck$596
- Johnson & Johnson$542
- Shionogi Inc$468
- plus $3K from 41 others
What the payments were for
- Consulting fees$90011%
- Speaking & faculty fees$461%
- Food & beverage$7,13785%
- Education$2693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,352 in reported general payments places this provider in the 90th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabenuvaCabotegravir/Rilpivirine | 56 | $376,241 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 69 | $298,667 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 63 | $264,230 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $188,478 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 34 | $167,105 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 41 | $154,919 |
| TivicayDolutegravir Sodium | 46 | $109,949 |
| PrezcobixDarunavir/Cobicistat | 39 | $97,933 |
| JulucaDolutegravir/Rilpivirine | 22 | $76,030 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 17 | $60,781 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $29,787 |
| Daptomycin | 33 | $27,926 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $26,589 |
| ErtapenemErtapenem Sodium | 16 | $8,469 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 12 | $7,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Triumeq, Tivicay, Juluca | $909 | $717,138165 claims |
| GileadBiktarvy, Genvoya, Descovy | $1,806 | $592,683144 claims |
| Insmed, Inc.Arikayce | $340 | $188,47812 claims |
| Johnson & JohnsonPrezcobix | $542 | $97,93339 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $15 | $26,58913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Hobart
- Mohammad AlkhatibHobart$3K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
- Darron BrownIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.